HC Wainwright Estimates Spyglass Pharma FY2025 Earnings

Key Points

• HC Wainwright forecasts Spyglass Pharma will report FY2025 EPS of ($19.06), maintains a Buy rating with a $37.00 target, and projects FY2026 EPS of ($2.21) alongside detailed quarterly estimates.
• Other analysts are mostly positive — Jefferies, Stifel and Citi initiated/maintained buys while Wall Street Zen and Zacks rate it a hold — leaving an average analyst price target of $45.00 and a consensus of "Moderate Buy."
• Ra Capital Management bought 3,690,000 shares at $16.00 (≈$59.0M), raising its stake to 5,966,439 shares; SGP recently traded near $27.10 with a 52‑week range of $20.16–$32.44.

Spyglass Pharma, Inc. (NASDAQ:SGP - Free Report) - Stock analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for Spyglass Pharma in a research report issued on Tuesday, March 10th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($19.06) per share for the year. HC Wainwright currently has a "Buy" rating and a $37.00 target price on the stock. HC Wainwright also issued estimates for Spyglass Pharma's Q4 2025 earnings at ($6.61) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.49) EPS, Q4 2026 earnings at ($0.49) EPS and FY2026 earnings at ($2.21) EPS.

SGP has been the subject of several other reports. Jefferies Financial Group began coverage on shares of Spyglass Pharma in a research report on Tuesday, March 3rd. They issued a "buy" rating and a $62.00 target price for the company. Wall Street Zen upgraded Spyglass Pharma to a "hold" rating in a research report on Tuesday, February 17th. Zacks Research upgraded Spyglass Pharma to a "hold" rating in a report on Wednesday, March 4th. Stifel Nicolaus began coverage on Spyglass Pharma in a research report on Tuesday, March 3rd. They set a "buy" rating and a $42.00 price objective on the stock. Finally, Citigroup initiated coverage on Spyglass Pharma in a report on Tuesday, March 3rd. They set a "buy" rating and a $42.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $45.00.

Spyglass Pharma Trading Up 1.0%

Spyglass Pharma stock opened at $27.10 on Thursday. Spyglass Pharma has a fifty-two week low of $20.16 and a fifty-two week high of $32.44.

Insider Activity

In related news, Director Ra Capital Management, L.P. bought 3,690,000 shares of the stock in a transaction dated Monday, February 9th. The stock was bought at an average price of $16.00 per share, with a total value of $59,040,000.00. Following the purchase, the director owned 5,966,439 shares in the company, valued at approximately $95,463,024. The trade was a 162.10% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Spyglass Pharma Company Profile

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.